Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Hypereosinophilic Syndrome – Phase 3 Japan Study
jRCT2080225231Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Benralizumab with Placebo/then benralizumab (2 arms). Started Jun 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on jRCT2080225231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225231.